China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SHE:300294)
China · Delayed Price · Currency is CNY 15.62
+0.06 (0.39%)
Jul 31, 2026, 3:04 PM CST
China Resources Boya Bio-pharmaceutical Group Co.,Ltd Employees
China Resources Boya Bio-pharmaceutical Group Co.,Ltd had 1,947 employees as of December 31, 2025. The number of employees increased by 9 or 0.46% compared to the previous year.
Employees
1,947
Change (1Y)
9
Growth (1Y)
0.46%
Revenue / Employee
947.27K CNY
Profits / Employee
1.76K CNY
Market Cap
7.88B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,947 | 9 | 0.46% |
| Dec 31, 2024 | 1,938 | 494 | 34.21% |
| Dec 31, 2023 | 1,444 | -246 | -14.56% |
| Dec 31, 2022 | 1,690 | 72 | 4.45% |
| Dec 31, 2020 | 1,618 | 7 | 0.43% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Star Lake Bioscience Co., Inc.Zhaoqing Guangdong | 10,528 |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 2,360 |
| Aurisco Pharmaceutical | 2,026 |
| Vcanbio Cell & Gene Engineering Corp., | 1,935 |
| Liaoning Chengda Biotechnology | 1,781 |
| Daan Gene | 1,506 |
| Chengdu Easton Biopharmaceuticals | 1,480 |
| Sino Biological,Inc. | 1,069 |
China Resources Boya Bio-pharmaceutical Group Co.,Ltd News
- 3 months ago - China Resources Boya Bio-pharmaceutical Group Co.,Ltd Quarterly report: Q1 2026 - Filings
- 4 months ago - China Resources Boya Bio-pharmaceutical Group Co.,Ltd Earnings release: H2 2025 - Filings
- 4 months ago - China Resources Boya Bio-pharmaceutical Group Co.,Ltd Annual report: H2 2025 - Filings
- 10 months ago - China Resources Boya Bio-pharmaceutical Group Co.,Ltd Quarterly report: Q3 2025 - Filings
- 1 year ago - China Resources Boya Bio-pharmaceutical Group Co.,Ltd Quarterly report: H1 2025 - Filings